Chesapeake Partners Management’s Tvardi Therapeutics TVRD Stock Holding History

Chesapeake Partners Management’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$4.62M	Sell	26,681 -1,009	-4%	-$220K	0.69%	27
2016 Q1	$6.2M	Buy	27,690 +10,519	+61%	+$3.14M	0.48%	42
2015 Q4	$10.4M	Buy	17,171 +250	+1%	+$137K	0.58%	60
2015 Q3	$8.71M	Buy	16,921 +856	+5%	+$573K	0.45%	72
2015 Q2	$7.03M	Buy	16,065 +9,088	+130%	+$3.51M	0.27%	90
2015 Q1	$2.52M	Buy	6,977 +2,524	+57%	+$955K	0.12%	90
2014 Q4	$1.6M	Hold	4,453	–	–	0.06%	103
2014 Q3	$1.34M	Hold	4,453	–	–	0.05%	108
2014 Q2	$2.73M	Hold	4,453	–	–	0.08%	104
2014 Q1	$2.98M	Buy	+4,453	New	+$2.63M	0.12%	91

Other funds holding TVRD

TAM

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Chesapeake Partners Management's TVRD Position: Q2 2016 in Review

Chesapeake Partners Management reduced its Tvardi Therapeutics (TVRD) stake by 3.6% in Q2 2016, selling an estimated $220K and leaving 26,681 shares worth $4.62M. The position accounts for 0.69% of the portfolio, ranked #27.

Chesapeake Partners Management first reported a position in TVRD in Q1 2014 and has held it in 10 quarters since. The position peaked at $10.4M in Q4 2015. 70 funds tracked by Wall St. Rank hold TVRD as of Q2 2016.

Chesapeake Partners Management held 26,681 shares of Tvardi Therapeutics worth $4.62M as of Q2 2016.
Chesapeake Partners Management sold 1,009 Tvardi Therapeutics shares in Q2 2016, an estimated $220K.
Tvardi Therapeutics made up 0.69% of Chesapeake Partners Management's portfolio in Q2 2016, its #27 holding.
Chesapeake Partners Management first reported a position in Tvardi Therapeutics in Q1 2014 and has held it in 10 quarters since.
Chesapeake Partners Management's Tvardi Therapeutics position peaked at $10.4M in Q4 2015.
70 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2016.

Based on Chesapeake Partners Management's 13F filing for Q2 2016, filed 15 Aug 2016.